Trevi Financial Statements From 2010 to 2025

TRVI Stock  USD 4.51  0.01  0.22%   
Trevi Therapeutics financial statements provide useful quarterly and yearly information to potential Trevi Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Trevi Therapeutics financial statements helps investors assess Trevi Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Trevi Therapeutics' valuation are summarized below:
Market Capitalization
403 M
Earnings Share
(0.44)
We have found one hundred twenty available fundamental trend indicators for Trevi Therapeutics, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Trevi Therapeutics current fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 63.2 M. Enterprise Value is estimated to decrease to about 64.4 M
Check Trevi Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trevi Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5.7 M, Discontinued Operations of 0.0 or Interest Expense of 696.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0407 or PTB Ratio of 0.78. Trevi financial statements analysis is a perfect complement when working with Trevi Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Trevi Therapeutics Correlation against competitors.
For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.

Trevi Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets56.3 M102.8 M38.7 M
Slightly volatile
Other Current Liabilities3.3 M4.3 M2.8 M
Slightly volatile
Total Current Liabilities7.3 M5.2 M13 M
Slightly volatile
Other Liabilities2.6 K2.7 K210.1 K
Slightly volatile
Accounts Payable1.7 M2.1 M1.2 M
Slightly volatile
Cash31.8 M37.3 M21.9 M
Slightly volatile
Cash And Short Term Investments100.2 M95.4 M33 M
Slightly volatile
Net Receivables243.5 K277.1 K152.8 K
Slightly volatile
Long Term Debt Total2.3 M2.5 M4.9 M
Pretty Stable
Other Current Assets5.5 M5.3 M1.2 M
Slightly volatile
Total Liabilities10.6 M6.2 M17.3 M
Slightly volatile
Total Current Assets55.5 M100.7 M38.1 M
Slightly volatile
Common Stock41.7 K78.2 K27.9 K
Slightly volatile
Property Plant Equipment201.5 K195.5 K117.4 K
Slightly volatile
Short and Long Term Debt Total1.5 M1.5 M5.3 M
Very volatile
Property Plant And Equipment Net1.9 M1.8 M414.6 K
Slightly volatile
Non Current Assets Total2.2 M2.1 M668.1 K
Slightly volatile
Non Currrent Assets Other341.9 K267.3 K247.8 K
Slightly volatile
Common Stock Shares Outstanding119.6 M113.9 M33.1 M
Slightly volatile
Liabilities And Stockholders Equity63 M102.8 M45.1 M
Slightly volatile
Non Current Liabilities Total1.1 M1.2 MM
Slightly volatile
Property Plant And Equipment GrossM1.9 M468.1 K
Slightly volatile
Non Current Liabilities Other4.3 K4.5 K191.9 K
Slightly volatile
Net Working Capital53.8 M94 M37.2 M
Slightly volatile
Capital Stock39.3 K61.2 K75.2 K
Slightly volatile
Capital Surpluse242.2 M365.2 M213.9 M
Slightly volatile
Capital Lease Obligations1.6 M1.5 M530 K
Slightly volatile
Current Deferred RevenueM3.4 M3.7 M
Slightly volatile

Trevi Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income5.7 M5.4 M2.3 M
Slightly volatile
Selling General Administrative7.6 M11.4 M5.3 M
Slightly volatile
Research Development18.6 M27.2 M13.9 M
Slightly volatile
Total Operating Expenses26.2 M39 M19.2 M
Slightly volatile
Depreciation And Amortization148.5 K141.4 K40.4 K
Slightly volatile
Reconciled Depreciation124.4 K118.5 K36.2 K
Slightly volatile
Selling And Marketing Expenses229.6 K258.3 K281.6 K
Slightly volatile

Trevi Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.6 M2.6 M969.3 K
Slightly volatile
Begin Period Cash Flow27.5 M14.5 M19.2 M
Slightly volatile
Depreciation148.5 K141.4 K40.4 K
Slightly volatile
Capital Expenditures93.5 K157.6 K63.1 K
Slightly volatile
End Period Cash Flow30.5 M37.3 M21.2 M
Slightly volatile
Change To Netincome2.2 M2.7 M1.4 M
Slightly volatile
Issuance Of Capital Stock4.5 M4.7 M19.5 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield0.04070.04580.0499
Slightly volatile
Capex To Depreciation1.221.282.7994
Slightly volatile
Inventory Turnover0.02490.04730.0284
Slightly volatile
Days Of Inventory On Hand7.6 KK16.1 K
Slightly volatile
Payables Turnover0.06430.06120.0258
Slightly volatile
Cash Per Share0.920.961.3461
Slightly volatile
Days Payables Outstanding5.9 K6.2 K24.8 K
Slightly volatile
Income Quality0.720.980.9349
Slightly volatile
Current Ratio14.2113.535.4813
Slightly volatile
Graham Number2.562.75.3539
Very volatile
Capex Per Share0.00150.00160.0026
Very volatile
Interest Debt Per Share0.01910.02010.7776
Slightly volatile
Debt To Assets0.01640.01721.2193
Slightly volatile
Operating Cycle7.6 KK16.1 K
Slightly volatile
Days Of Payables Outstanding5.9 K6.2 K24.8 K
Slightly volatile
Ebt Per Ebit1.220.991.173
Slightly volatile
Effective Tax Rate0.00180.00130.0013
Pretty Stable
Total Debt To Capitalization0.01740.01832.1367
Slightly volatile
Quick Ratio14.2113.535.4188
Slightly volatile
Net Income Per E B T0.80.90.9802
Slightly volatile
Cash Ratio3.845.013.1076
Slightly volatile
Days Of Inventory Outstanding7.6 KK16.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9837
Slightly volatile
Debt Ratio0.01640.01721.2193
Slightly volatile

Trevi Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap63.2 M119.4 M98.6 M
Slightly volatile

Trevi Fundamental Market Drivers

Cash And Short Term Investments83 M

Trevi Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Trevi Therapeutics Financial Statements

Investors use fundamental indicators, such as Trevi Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Trevi Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue3.4 MM
Cost Of Revenue141.4 K148.5 K

Currently Active Assets on Macroaxis

When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:
Check out the analysis of Trevi Therapeutics Correlation against competitors.
For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.44)
Return On Assets
(0.37)
Return On Equity
(0.60)
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.